Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction
Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction
This study will evaluate how well different medications work to relieve pain following third
 molar (wisdom tooth) extraction. Scientists believe that hormone-like substances called
 prostanoids contribute to pain following oral surgery. Prostanoids are produced by
 cyclooxygenase (COX) enzymes. This study will examine how different medicines inhibit the COX
 enzymes and reduce the amount of prostanoids, and thus the amount of inflammation and pain.
 The study will also look at genetic factors involved in the production of prostanoids and the
 response to pain medication. (Only the bottom two wisdom teeth are extracted for this study.
 Patients whose top wisdom teeth also need to be removed will have those teeth extracted, also
 free of charge, at least 2 weeks after the first surgery.)

 Healthy normal volunteers between 16 and 35 years of age who are in general good health and
 who require third molar extraction may be eligible for this study. Candidates are screened
 with a medical history and oral examination, including dental x-rays as needed to confirm the
 need for third molar removal.

 On the morning of surgery, patients have blood drawn to obtain DNA for genetic study. Women
 of childbearing age have a urine pregnancy test. One hour before surgery, patients receive a
 dose of rofecoxib (Vioxx® (Registered Trademark)), acetaminophen (Tylenol® (Registered
 Trademark)), or placebo (a pill with no active ingredient). A half-hour before surgery, they
 receive either a standard painkiller called keterolac (Toradol® (Registered Trademark))) or
 placebo through an arm vein. All patients also receive the sedative midazolam (Versed®
 (Registered Trademark)), also through an arm vein, to induce drowsiness and a local
 anesthetic (lidocaine) to numb the mouth. After the mouth is numbed, but before the wisdom
 teeth are extracted, a biopsy (removal of a small piece of tissue) is conducted in the area
 of the cheek next to the wisdom tooth.

 After the surgery, a small piece of tubing is placed into both extraction sites. Every 20
 minutes for the next 3 hours, inflammatory fluid is collected from the tubing to measure
 chemicals that are believed to cause pain and swelling. Patients complete questionnaires
 every 20 minutes to rate their pain. Those who still have pain an hour after surgery may
 request and receive a "rescue drug" called tramadol (Ultram® (Registered Trademark)) for pain
 relief. Patients remain in the clinic from 3 to 6 hours to monitor the effects of the study
 drugs as the anesthetic wears off.

 After surgery a second biopsy is done to measure any changes in the chemicals being produced
 in response to the surgery. For this biopsy, patients are assigned to one of two groups - one
 group has the second biopsy within 3 hours of surgery, before taking the rescue drug, and the
 other group returns to the clinic the next morning for a biopsy 24 hours after surgery.
 Patients in the second group leave the clinic after surgery with two pain medications
 (tramadol and the study drug) and forms to record pain ratings at home. They are permitted to
 take only the pain medications provided and only at certain times.

 At the end of their participation in the study, all patients are given the pain medication
 flurbiprofen (Ocufen® (Registered Trademark)) to take at home.
Two cyclooxygenase isozymes, COX-1 and -2, are known to catalyze the rate-limiting step of
 prostaglandin synthesis and are the targets of nonsteroidal anti-inflammatory drugs.
 Recently, the presence of a variant of COX-1, named COX-3, has been demonstrated that is
 especially sensitive to acetaminophen and strongly expressed in brain tissue. The proposed
 study will examine prostanoid suppression in the periphery by inhibition of COX-1, -2, and
 -3, and evaluate the time course of expression of COX isoenzymes in terms of level of mRNA
 and protein itself.

 Subjects (N equals 88) will be healthy volunteers scheduled for the surgical removal of
 impacted third molars. Using a double-blinded, randomized, parallel study design, subjects
 will be allocated to one of four treatment groups and will be administered a dose of blinded
 medication or placebo. One hour prior to oral surgery, rofecoxib 50 mg, acetaminophen 1000 mg
 or placebo in two groups will be administered orally. Half hour prior to surgery, ketorolac
 30 mg or placebo, will be administered intravenously. Microdialysis will be performed with
 sample collection concurrent with pain report over the immediate postoperative period of
 three hours, and the collected transudate will be analyzed by ELISA to evaluate prostanoid
 (prostaglandin E2, thromboxane B2) production. Subjects within each group will be further
 randomized to have a biopsy collected at baseline prior to surgery and either at the time
 when a subject asks for rescue drug within 3 hours or at 24 hours following surgery. The
 biopsies will be frozen in liquid nitrogen and assayed later by RT-PCR for levels of COX-1,
 COX-2, or COX-3 mRNA, and by microarray for evaluation of change in overall mRNA expression.
 A portion of the biopsy samples will be immunostained to reveal the tissue-specific pattern
 of each COX isoenzymes expression within the inflammatory tissue, and another part of the
 biopsy samples will be analyzed by Western blot to quantify the amount of protein. Fifty ml
 of blood will be collected from all subjects, and the single nucleotide polymorphisms (SNPs)
 in the genes regulated by inflammatory responses such as COX-1, COX-2, PGE receptors (EPs),
 and microsomal PGE synthase (mPGES) genes, will be analyzed to investigate the role of
 genetic factors in individual differences of drug responses. The analgesic effect of the
 drugs will be assessed in the clinic every 20 minutes for the first three hours after
 extractions, and on the next morning before taking any medication using two pain intensity
 assessment instruments: a category scale, and a visual analog scale (VAS).

 We anticipate that non-selective COX inhibitor, the selective COX-2 inhibitor, and the
 selective COX-3 inhibitor will differentially alter prostanoid production over the time
 course evaluated, and that primary sensory neurons innervating in the inflammatory tissues
 may differentially express COX isoenzymes that differ in sensitivity to prototypic NSAIDs,
 coxibs, and acetaminophen. We also anticipate that several SNPs will contribute to the
 individual differences in COX expression and drug responses, which has implications for
 individual variation in pain, analgesic responses, and neuronal plasticity.
INCLUSION CRITERIA:

 Male or female volunteers referred for third molar extraction willing to undergo 2 or 3
 visits: 1 screening visit; 1 surgical appointment; and possible 1 follow-up
 research-related appointment

 Between the ages of 16 to 35 years (based upon eruption patterns and age-related
 complications associated with surgical extraction of third molars)

 In general good health- American Society of Anesthesiologists (ASA) status I or II (healthy
 subjects based upon criteria for safe administration of out-patient conscious sedation)

 Willing to undergo observation period for three hours postoperatively

 Ability to complete a 100 mm visual analog scale and a category scale every 20 minutes for
 the first 3 postoperative hours

 Willing to have a microdialysis probe placed beneath the surgical flap during the first 3
 hours post-surgery

 Willing to have a preoperative biopsy on the day of surgery, and a postoperative biopsy
 either within 3 hours or at 24 hours following surgery

 Willing to return, if needed, 24 hours post-operation for the postoperative biopsy

 Must have two lower partial bony impacted wisdom teeth fully covered by intact soft tissue
 (rating equals 3) or fully bony impacted (rating equals 4) wisdom teeth (mandibular third
 molars)

 As assessed at the screening visit, the sum of the mandibular third molar surgical
 difficulty ratings must be between 6 to 8 in order to evaluate subjects experiencing
 similar pain levels

 EXCLUSION CRITERIA:

 Patients who are allergic to aspirin, NSAIDs, sulfites, or amide anesthetics

 Patients who have had asthma, or hives

 Patients who are pregnant or nursing

 Patients with history of peptic ulcers and/or GI bleeding

 Chronic use of medications confounding the assessment of the inflammatory response or
 analgesia, for example, NSAIDs, COX-2 inhibitors, antihistamines, steroids, antidepressants

 Patients who have significant psychiatric history

 Patients who have a clinical signs suggestive of infection, inflammation, or pre-existing
 pain at either extraction site

 Patients with severe kidney disease

 Patients who are taking any of the following drugs: ACE inhibitor; potassium sparing
 diuretics; aspirin on a near daily basis; coumadin or other blood thinners

 Patients who are taking drugs known to inhibit P450 2C9 and drugs metabolized by P450 2D6

 Patients who have G6PD deficiency and those taking St. John's Wort

 Unusual surgical difficulty (determined from panoramic radiograph or during the actual
 surgery)